Modality
mAb
MOA
SOS1i
Target
AuroraA
Pathway
Tau
DLBCLDravet
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
Jan 2020
→ Apr 2025
Phase 1Current
NCT07173503
2,380 pts·Dravet
2020-01→2025-04·Recruiting
2,380 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-1611mo agoInterim· Dravet
2026-07-244mo awayPh1 Dose Esc· Dravet
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1
Recruit…
Catalysts
Interim
2025-04-16 · 11mo ago
Dravet
Ph1 Dose Esc
2026-07-24 · 4mo away
Dravet
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07173503 | Phase 1 | Dravet | Recruiting | 2380 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA |